Globus Medical, Inc., a medical device company, develops and markets healthcare solutions for patients with musculoskeletal disorders. The company is headquartered in Audubon, Pennsylvania.
| Revenue (TTM) | $3.14B |
| Gross Profit (TTM) | $2.17B |
| EBITDA | $1.01B |
| Operating Margin | 24.80% |
| Return on Equity | 11.80% |
| Return on Assets | 8.74% |
| Revenue/Share (TTM) | $23.32 |
| Book Value | $35.52 |
| Price-to-Book | 2.20 |
| Price-to-Sales (TTM) | 3.34 |
| EV/Revenue | 3.181 |
| EV/EBITDA | 10.49 |
| Quarterly Earnings Growth (YoY) | -26.20% |
| Quarterly Revenue Growth (YoY) | 5.90% |
| Shares Outstanding | $111.83M |
| Float | $110.20M |
| % Insiders | 0.61% |
| % Institutions | 92.01% |
Volatility is currently contracting
Excelsius3D™ – Intelligent 3-in-1 Imaging System Expands Excelsius™ Ecosystem in the European Union Excelsius3D™ – Intelligent 3-in-1 Imaging System Expands Excelsius™ Ecosystem in the European Union
Globus Medical (GMED) could produce exceptional returns because of its solid growth attributes.
The mean of analysts' price targets for Globus Medical (GMED) points to a 25% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Investors looking for stocks in the Medical - Instruments sector might want to consider either Globus Medical (GMED) or Integer (ITGR). But which of these two stocks is more attractive to value investors?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
PEG-driven GARP picks EnerSys, Globus Medical, DoubleVerify and Match Group pair discounted valuations with strong growth potential.
Globus Medical is rated a buy, targeting a 17.5% return over four quarters with a constant 10.56x EV/EBITDA multiple. GMED's base business is compounding faster than headline growth, with international sales rising 18% and gross margin expanding by 200bps, excluding accounting effects. SG&A leverage drove operating margin improvement, while integration of Nevro remains a known, sized, and management-dated drag.
Globus Medical (GMED) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Globus Medical (GMED) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on GMED and any ticker you trade — then tracks every position and per-strategy win rate.
